Insulin Glargine Market Synopsis:

Insulin Glargine Market Size Was Valued at USD 5.44 Billion in 2023, and is Projected to Reach USD 8.42 Billion by 2032, Growing at a CAGR of 6.3% From 2024-2032.

The insulin glargine market concerns with the segment associated with the manufacturing, selling, and marketing of insulin glargine, which is a long-acting insulin analogue primarily utilised in the treatment of diabetes mellitus. It stabilises blood glucose levels as it is an artificial insulin that resembles the workings of the human hormone, but with a steady and long-lasting action. I think this drug represents a central component of management regimes for not only those with type one but type two diabetes as well especially where the need to take insulin cannot be overemphasized both locally and internationally.

The insulin glargine market has rapidly evolved over the last decade, where there is increased awareness of the existence of diabetes. Since the World Health Organization indicated a worrisome increasing trend in the incidence of diabetes especially type 2 diabetes, the need for adequate insulin treatments has equally increased. Stable and having a long action time is the most recent development which is well liked both by physicians and patients – insulin glargine. This has called for increased research and development carried out with the intent of improving insulin formulations as well as systems of delivery.

Besides the growing cases of diabetes, several other factors are contributing to market growth. These are due to increasing awareness in diabetes management, blood glucose control needs and probably improved diagnostic services. However, due to recent technological development in insulin delivery devices such as prefilled pens and smart insulin pumps, patient compliance and convenience have greatly improved. The field is also influenced by different approvals of regulations which create rivalry and advancements to the Pharma franchises. Therefore, from the above analysis it is anticipated that the market of insulin glargine will maintain its steady growth in the near future due to strong pipeline of new products and introduction of biosimilar.

Insulin Glargine

Insulin Glargine Market Trend Analysis:

 Increased Adoption of Biosimilars.

  • Another significant factor observed in the current insulin glargine market is the rising popularity of biosimilars, which are biologic MCPs that are highly similar to reference product. Human remedy|Among some of the new trends that have been observed in the market of insulin glargine are as follows: Biosimilars that refer to biologic MCPs that are closely similar to an already approved reference product. When patents on the first-generation glargine_STARTED formulations come up for expiry several firms are expected to launch low-cost biosimilars. This change is believed to improve the availability of critical diabetes care products in the market to address the need of the population in the emerging markets that is characterized by high cost of care. In addition to promoting competitive pricing, the entry of the biosimilars also enhances novelty since manufacturers will invent new ways of developing the products.

 Growing Demand in Emerging Market.

  • The insulin glargine market is viewed to have the good potential especially in tier two and tier three economy countries experiencing increase in the incidence of diabetes mellitus. Other large and emerging markets, for example, India, China and Brazil are growing their healthcare spend in addition to developing better access to diabetes care; more individuals with diabetes require effective insulin treatment. These regions are usually associated with unavailability and high cost of healthcare; thus, the potential market for insulin glargine products is high for the companies that will be able to offer affordable products. Furthermore, collaboration with local medical care organizations as well as other state programs, aimed at the improvement of diabetes treatment, can also contribute to the progressive penetration and subsequent growth of the market opportunities in these regions with the highest growth potential.

Insulin Glargine Market Segment Analysis:

Insulin Glargine Market is Segmented on the basis of Type, Diabetes Distribution channel, and Region

By Type, Lantus, segment is expected to dominate the market during the forecast period

  • Lantus segment expected to dominate the market share of close to 42.7% in 2024. Lantus, the first long-acting insulin analogue in the market, has built up strong brand awareness with patients and doctors in the last two decades. Because of that, it remains the popular choice of many diabetes patients due to its ability to regulate blood sugar levels in the body at any time of the day through a single dose. Notably, Lantus is packaged in prefilled pen devices, whose use and adherence have been greatly enhanced as compared to vials.

  • Nevertheless, possible cost savings of Basaglar and renewed formulas of Toujeo are counterbalanced by the fact that patients still do not want to change Lantus that has long been helping them to keep their blood sugar levels under control. Physicians are also extremely careful while using alternates because diabetes is a sensitive disease and the management of this disease requires certain clinical reasons. Lantus is likely therefore to maintain its high market share through the influence of long brand loyalty and patient preferences accrued over its long history except if they seek to introduce product to the market with demonstrably better result.

By Distribution Channel, Hospital Pharmacies segment expected to held the largest share

  • Distribution channel segment is further segmented into hospital pharmacy, Retail pharmacy, and online pharmacies. Among the 5 segment retail pharmacies segment has the largest share in insulin glargine market and is expected to reach 39.2 % in 2024. Due to convenience, it also found that retail pharmacies are now the first point of call for most Type 2 diabetes patients to refill their insulin prescriptions. Time constrained consumers prefer to obtain their insulin supplies from chemists and other products during their weekly trips. This is more convenient for them compared with dealing with numerous hospital or specialty pharmacy trips.

  • More doctors are available for appointment as most of the shops and stores operate for long their with many outlets making access easy. In the view of the patient, reduction of the likelihood of experiencing adverse effects due to wrong insulin storage or application is desirable. It is as a result moot to allow the retail pharmacists to counsel and even supervise the use during the initialization period. This plays a big role in motivating compliance with insulin therapy and consequently minimizing health risks and disease prognosis in the long term.

Insulin Glargine Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • North America remains the largest consumer of insulin glargine in 2023 capturing 45 percent of the global market. One of these strengths is the healthcare supportive industry in the region, adherence to the disease among people, and a large number of investment on research and innovation. The largest market is the United States due to the opportunity of the high incidence of diabetes and the availability of the largest pharmaceutical companies that develop various types of insulin. Also increased patient compliance and good management of diabetes have also been made possible by the use of improved insulin delivery services like insulin pen and pump. The market leadership of North America will remain unchallenged by other regions due to the increasing number of healthcare policies and availability of insulin therapies for a bigger market population.

  • This penetration is explained by a high number of people with diabetes and millions of patients who need basal insulin to achieve good glucoregulation. Especially the United States is a large contributor in this market due to a well developed healthcare industry, research and development capabilities and domestic players in insulin manufacturing. Thirdly, improvement in knowledge about the moderating of diabetes and enhanced call for enhanced health care have led to the enhanced use of insulin glargine products. Competition is also shifting with biosimilars intervention the primary niche cheaper solutions that enhance patients’ availability. Such biosimars along with regulatory support for these furthers the market growth of these biosimars and insulin glargine ensuring that North America continues to remain strategically poised for the insulin glargine market in the coming years.

Active Key Players in the Insulin Glargine Market:

  • Amgen Inc. (USA)  GSK (UK)

  • AstraZeneca (UK)
  • Boehringer Ingelheim (Germany)
  • Eli Lilly and Company (USA)
  • Janssen Pharmaceuticals (USA)
  • Merck & Co. (USA)
  • Mylan N.V. (USA)
  • Novo Nordisk (Denmark)
  • Pfizer Inc. (USA)
  • Sandoz (Switzerland)
  • Sanofi (France)
  •  Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Other Active players.

Global Insulin Glargine Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 5.44   Billion

Forecast Period 2024-32 CAGR:

6.3%

Market Size in 2032:

USD 8.42  Billion

Segments Covered:

By Type

  • Type:
  • Lantus
  • Basaglar
  • Toujeo
  • Soliqua/Suliqua
  • Others

By Diabetes

  • Diabetes Type:
  • Type 2 Diabetes
  • Type 1 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  •  Increased Adoption of Biosimilars

Key Market Restraints:

  • High cost

Key Opportunities:

  •  Growing Demand in Emerging Markets

Companies Covered in the report:

  • Sanofi, Eli Lilly and Company, Novo Nordisk, Merck & Co. and Other Active Players.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Insulin Glargine Market by Type
 4.1 Insulin Glargine Market Snapshot and Growth Engine
 4.2 Insulin Glargine Market Overview
 4.3 Lantus
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Lantus : Geographic Segmentation Analysis
 4.4 Basaglar
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Basaglar : Geographic Segmentation Analysis
 4.5 Toujeo
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Toujeo : Geographic Segmentation Analysis
 4.6 Soliqua/ Suliqua
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Soliqua/ Suliqua : Geographic Segmentation Analysis
 4.7 Others
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Others: Geographic Segmentation Analysis

Chapter 5: Insulin Glargine Market by Diabetes Type
 5.1 Insulin Glargine Market Snapshot and Growth Engine
 5.2 Insulin Glargine Market Overview
 5.3 Type 2 Diabetes
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Type 2 Diabetes : Geographic Segmentation Analysis
 5.4 Type 1 Diabetes
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Type 1 Diabetes: Geographic Segmentation Analysis

Chapter 6: Insulin Glargine Market by Distribution Channel
 6.1 Insulin Glargine Market Snapshot and Growth Engine
 6.2 Insulin Glargine Market Overview
 6.3 Hospital Pharmacies
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospital Pharmacies : Geographic Segmentation Analysis
 6.4 Retail Pharmacies
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Retail Pharmacies : Geographic Segmentation Analysis
 6.5 Online Pharmacies
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Online Pharmacies: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Insulin Glargine Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions  
 7.2 AMGEN INC. (USA)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 GSK (UK)
 7.4 ASTRAZENECA (UK)
 7.5 BOEHRINGER INGELHEIM (GERMANY)
 7.6 ELI LILLY AND COMPANY (USA)
 7.7 JANSSEN PHARMACEUTICALS (USA)
 7.8 MERCK & CO. (USA)
 7.9 MYLAN N.V. (USA)
 7.10 NOVO NORDISK (DENMARK)
 7.11 PFIZER INC. (USA)
 7.12 SANDOZ (SWITZERLAND)
 7.13 SANOFI (FRANCE)
 7.14 SUN PHARMACEUTICAL INDUSTRIES LTD. (INDIA)
 7.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
 7.16 .
 7.17 OTHER ACTIVE PLAYERS

Chapter 8: Global Insulin Glargine Market By Region
 8.1 Overview
8.2. North America Insulin Glargine Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Type
  8.2.4.1 Lantus
  8.2.4.2 Basaglar
  8.2.4.3 Toujeo
  8.2.4.4 Soliqua/ Suliqua
  8.2.4.5 Others
  8.2.5 Historic and Forecasted Market Size By Diabetes Type
  8.2.5.1 Type 2 Diabetes
  8.2.5.2 Type 1 Diabetes
  8.2.6 Historic and Forecasted Market Size By Distribution Channel
  8.2.6.1 Hospital Pharmacies
  8.2.6.2 Retail Pharmacies
  8.2.6.3 Online Pharmacies
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
8.3. Eastern Europe Insulin Glargine Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Type
  8.3.4.1 Lantus
  8.3.4.2 Basaglar
  8.3.4.3 Toujeo
  8.3.4.4 Soliqua/ Suliqua
  8.3.4.5 Others
  8.3.5 Historic and Forecasted Market Size By Diabetes Type
  8.3.5.1 Type 2 Diabetes
  8.3.5.2 Type 1 Diabetes
  8.3.6 Historic and Forecasted Market Size By Distribution Channel
  8.3.6.1 Hospital Pharmacies
  8.3.6.2 Retail Pharmacies
  8.3.6.3 Online Pharmacies
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Russia
  8.3.7.2 Bulgaria
  8.3.7.3 The Czech Republic
  8.3.7.4 Hungary
  8.3.7.5 Poland
  8.3.7.6 Romania
  8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Insulin Glargine Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Type
  8.4.4.1 Lantus
  8.4.4.2 Basaglar
  8.4.4.3 Toujeo
  8.4.4.4 Soliqua/ Suliqua
  8.4.4.5 Others
  8.4.5 Historic and Forecasted Market Size By Diabetes Type
  8.4.5.1 Type 2 Diabetes
  8.4.5.2 Type 1 Diabetes
  8.4.6 Historic and Forecasted Market Size By Distribution Channel
  8.4.6.1 Hospital Pharmacies
  8.4.6.2 Retail Pharmacies
  8.4.6.3 Online Pharmacies
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 The Netherlands
  8.4.7.5 Italy
  8.4.7.6 Spain
  8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Insulin Glargine Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Type
  8.5.4.1 Lantus
  8.5.4.2 Basaglar
  8.5.4.3 Toujeo
  8.5.4.4 Soliqua/ Suliqua
  8.5.4.5 Others
  8.5.5 Historic and Forecasted Market Size By Diabetes Type
  8.5.5.1 Type 2 Diabetes
  8.5.5.2 Type 1 Diabetes
  8.5.6 Historic and Forecasted Market Size By Distribution Channel
  8.5.6.1 Hospital Pharmacies
  8.5.6.2 Retail Pharmacies
  8.5.6.3 Online Pharmacies
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
8.6. Middle East & Africa Insulin Glargine Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Type
  8.6.4.1 Lantus
  8.6.4.2 Basaglar
  8.6.4.3 Toujeo
  8.6.4.4 Soliqua/ Suliqua
  8.6.4.5 Others
  8.6.5 Historic and Forecasted Market Size By Diabetes Type
  8.6.5.1 Type 2 Diabetes
  8.6.5.2 Type 1 Diabetes
  8.6.6 Historic and Forecasted Market Size By Distribution Channel
  8.6.6.1 Hospital Pharmacies
  8.6.6.2 Retail Pharmacies
  8.6.6.3 Online Pharmacies
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkiye
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
8.7. South America Insulin Glargine Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Type
  8.7.4.1 Lantus
  8.7.4.2 Basaglar
  8.7.4.3 Toujeo
  8.7.4.4 Soliqua/ Suliqua
  8.7.4.5 Others
  8.7.5 Historic and Forecasted Market Size By Diabetes Type
  8.7.5.1 Type 2 Diabetes
  8.7.5.2 Type 1 Diabetes
  8.7.6 Historic and Forecasted Market Size By Distribution Channel
  8.7.6.1 Hospital Pharmacies
  8.7.6.2 Retail Pharmacies
  8.7.6.3 Online Pharmacies
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
 

Global Insulin Glargine Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 5.44   Billion

Forecast Period 2024-32 CAGR:

6.3%

Market Size in 2032:

USD 8.42  Billion

Segments Covered:

By Type

  • Type:
  • Lantus
  • Basaglar
  • Toujeo
  • Soliqua/Suliqua
  • Others

By Diabetes

  • Diabetes Type:
  • Type 2 Diabetes
  • Type 1 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  •  Increased Adoption of Biosimilars

Key Market Restraints:

  • High cost

Key Opportunities:

  •  Growing Demand in Emerging Markets

Companies Covered in the report:

  • Sanofi, Eli Lilly and Company, Novo Nordisk, Merck & Co. and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Insulin Glargine Market research report?
The forecast period in the Insulin Glargine Market research report is 2024-2032.
Who are the key players in the Insulin Glargine Market?
Amgen Inc. (USA), GSK (UK), AstraZeneca (UK), Boehringer Ingelheim (Germany), Eli Lilly and Company (USA), Janssen Pharmaceuticals (USA), Merck & Co. (USA), Mylan N.V. (USA), Novo Nordisk (Denmark), Pfizer Inc. (USA), Sandoz (Switzerland), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Other Active Players.
What are the segments of the Insulin Glargine Market?
The Insulin Glargine Market is segmented into Type, By Diabetes , Distribution Channel. By Type, the market is categorized into Lantus , Basaglar , Toujeo ,Soliqua/ Suliqua ,Others), BY Diabetes Type The Marked is Categorized into (Type 2 Diabetes ,Type 1 Diabetes) By Distribution Channel, the market is categorized into Hospital Pharmacies Retail Pharmacies Online Pharmacie) , it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
What is the Insulin Glargine Market?
The insulin glargine market concerns with the segment associated with the manufacturing, selling, and marketing of insulin glargine, which is a long-acting insulin analogue primarily utilised in the treatment of diabetes mellitus. It stabilises blood glucose levels as it is an artificial insulin that resembles the workings of the human hormone, but with a steady and long-lasting action. I think this drug represents a central component of management regimes for not only those with type one but type two diabetes as well especially where the need to take insulin cannot be overemphasized both locally and internationally.
How big is the Insulin Glargine Market?
Insulin Glargine Market Size Was Valued at USD 5.44 Billion in 2023, and is Projected to Reach USD 8.42 Billion by 2032, Growing at a CAGR of 6.3% From 2024-2032.